Corpus overview


Overview

MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus


SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Prevalence and Risk Factors of Thrombotic Events on Patients with COVID-19 MESHD: A Systematic Review and Meta-Analysis

    Authors: Xiaoming Xiong; Jianhua Chi; Qinglei Gao

    doi:10.21203/rs.3.rs-80187/v1 Date: 2020-09-18 Source: ResearchSquare

    BackgroundCoagulation abnormalities in COVID-19 MESHD patients accompanied with poor prognosis.This study aimed to determine the prevalence and risk factors of thrombotic MESHD events on COVID-19 MESHD patients.MethodsWe systematically reviewed all the studies about thrombotic MESHD events on COVID-19 MESHD patients in PubMed, Embase, Web of Science, MedRxiv, bioRxiv, from Dec 1st, 2019 to July 5, 2020. The weighted mean difference (MD) or odds ratio (OR) or relative risk (RR) with 95% confidence intervals (CI) for clinical data in COVID-19 MESHD patients with or without thrombotic MESHD events was calculated. Results12 articles contained 1083 patients were included for meta-analysis. The prevalence of thrombosis MESHD was 22% (95% CI 0.08-0.40) in COVID-19 MESHD patients and increased to 43% (95% CI 0.29-0.65) after admission to the intensive care unit (ICU). Compared with non-thrombotic MESHD patients, thrombotic MESHD patients had higher levels of D-dimer (MD=2.79, 95% CI 2.27–3.31), lactate dehydrogenase (LDH) (MD=112.71, 95% CI 62.40–163.02), and white blood cells (WBC) (MD=1.14, 95% CI 0.47–1.81) while decreased lymphocytes (MD= -0.20, 95% CI -0.38 – -0.02). Age, platelet counts, and male sex tended to be risks while diabetes MESHD tended to be a protection for thrombosis MESHD for COVID-19 MESHD patients, although no statistical difference was achieved. Finally, patients with thrombosis MESHD were at a higher risk of death MESHD (OR=2.39, 95% CI 1.36–4.20).ConclusionsPrevalence of thrombosis MESHD in COVID-19 MESHD patients was high, especially in ICU, though pharmacologic thromboembolism MESHD prophylaxis was applied. Therefore, higher levels of D-dimer, LDH, WBC, and decreased lymphocytes needed to be paid close attention to in patients with COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.